Approval · Notice of Compliance 24409 · 2020
ATORVASTATIN: Notice of Compliance 24409
Issued October 8, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24409
- Date
- October 8, 2020
- Company
- Angita Pharma Inc.Boucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Canadian reference product
- LIPITOR (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ATORVASTATIN | 02506076 | Marketed |
| ATORVASTATIN | 02506084 | Marketed |
| ATORVASTATIN | 02506092 | Marketed |
| ATORVASTATIN | 02506106 | Marketed |
Medicinal ingredients
- ATORVASTATIN CALCIUM 10 MG per TAB
- ATORVASTATIN CALCIUM 20 MG per TAB
- ATORVASTATIN CALCIUM 40 MG per TAB
- ATORVASTATIN CALCIUM 80 MG per TAB